In Episode 3 of Roadmap to Rare, host Eric Finn is joined by Dr. Gabrielle Rushing, Chief Scientific Officer for the CSNK2A1 Foundation, and Dr. Elena Bagatelas. Together, they unpack the science behind Okur-Chung Neurodevelopmental Syndrome (OCNDS), from explaining the functions of the CNSK2A1 gene and the CK2 protein, to talking about the foundation’s genotype (genetic code)-phenotype (physical result) research, patient registries, and current research priorities. The researchers highlight that every family’s participation helps move research forward.
Subscribe so you can stay updated for new episodes! New episodes every two weeks.
Your ideas help shape the conversations that matter most to the rare disease community. Feel free to submit questions and topics of interest to us: https://www.csnk2a1foundation.org/roadmap-to-rare-podcast
Stay Connected:
Visit our website: https://www.csnk2a1foundation.org/
Follow us on Instagram: @csnk2a1_foundation
Follow us on Facebook: CSNK2A1 Foundation
Follow us on LinkedIn: CSNK2A1 Foundation
Links & Resources:
https://www.simonssearchlight.org/research/what-we-study/csnk2a1/
https://www.csnk2a1foundation.org/simons-searchlight
https://www.csnk2a1foundation.org/citizen-health
https://www.csnk2a1foundation.org/project-find-out
https://www.csnk2a1foundation.org/new-partnership-with-probably-genetic
Bagatelas et al., 2025. OCNDS core features are conserved across variants with loop-region mutations driving greater symptom burden: https://pmc.ncbi.nlm.nih.gov/articles/PMC12267189/